Skip to main content
CMEducation Resources ScrollCall
  • menu
  • menu
  • person
  • Search
  • Specialty
  • Cardiology chevron_right

  • Specialty Program
  • Fabry Disease chevron_right
  • Hypothyroidism chevron_right
  • Pain Management chevron_right
  • Glycemic Regulation chevron_right
  • PCSK9s in Interventional Cardiology chevron_right
  • PCSK9s in Medical Preventative chevron_right
  • PCSK9s in Lipid Medicine & Atherosclerosis Prevention chevron_right
  • PCSK9s in Diabetes Management chevron_right
  • PCSK9s: A Multi-Specialty Perspective chevron_right
  • Specialty
  • Diabetes chevron_right

  • Specialty Program
  • Fabry Disease chevron_right
  • Hypothyroidism chevron_right
  • Glycemic Regulation chevron_right
  • PCSK9s in Diabetes Management chevron_right
  • Specialty Program
  • Congenital Adrenal Hyperplasia (CAH) chevron_right
  • Cytokine Immunotherapy chevron_right
  • Hypothyroidism chevron_right
  • Specialty Program
  • Parkinson's Diseasechevron_right
  • Specialty
  • Cancer chevron_right

  • Specialty Program
  • Cytokine Immunotherapy chevron_right
  • Extracorporeal Photopheresis (ECP) chevron_right
  • Pain Management chevron_right
  • Specialty
  • Primary Care chevron_right

  • Specialty Program
  • Atopic Dermatitischevron_right
  • Congenital Adrenal Hyperplasia (CAH) chevron_right
  • Fabry Disease chevron_right
  • Hypothyroidism chevron_right
  • Parkinson's Diseasechevron_right
  • Pain Management chevron_right
  • Glycemic Regulation chevron_right
  • Specialty
  • Dermatology chevron_right

  • Specialty Program
  • Atopic Dermatitischevron_right
  • Cytokine Immunotherapy chevron_right
  • Fabry Disease chevron_right
  • Extracorporeal Photopheresis (ECP) chevron_right
  • Specialty
  • Biologicschevron_right

  • Specialty Program
  • Atopic Dermatitischevron_right
  • Cytokine Immunotherapy chevron_right
  • Fabry Disease chevron_right
  • Biosimilars for RA chevron_right
  • PCSK9s in Interventional Cardiology chevron_right
  • PCSK9s in Medical Preventative chevron_right
  • PCSK9s in Lipid Medicine & Atherosclerosis Prevention chevron_right
  • PCSK9s in Diabetes Management chevron_right
  • PCSK9s: A Multi-Specialty Perspective chevron_right
  • Specialty
  • MAC Lung Disease chevron_right

  • Specialty Program
  • MAC Lung Disease chevron_right
    • close
    CMEducation Resources iQ&A
    • person
    • Home
    • Specialtieschevron_right
      • chevron_leftTopics
      • Cardiology
      • Diabetes
      • Endocrinology
      • Neurology
      • Cancer
      • Primary Care
      • Dermatology
      • Biologics
      • MAC Lung Disease
    • Submit A Question
    close

    Shaun Goodman, MD, MSc, FRCPC, FACC, FESC, FAHA

    Associate Head, Division of Cardiology

    Shaun Goodman, MD, MSc, FRCPC, FACC, FESC, FAHA

    Associate Head, Division of Cardiology 

    St. Michael’s Hospital 

    Professor, Department of Medicine 

    University of Toronto 

    Toronto, Ontario


    Related Videos

    How have the 2016 Canadian Cardiovascular Society Guidelines for LDL-C reduction positioned their recommendations for LDL-C target goals, and how do you anticipate these might change in the future based on the ODYSSEY Outcomes and FOURIER Trials? Video

    How have the 2016 Canadian Cardiovascular Society Guidelines for LDL-C reduction positioned their recommendations for LDL-C target goals, and how do you anticipate these might change in the future based on the ODYSSEY Outcomes and FOURIER Trials?

    What did ODYSSEY Outcomes and FOURIER teach us about high-risk patients with diabetes and the relative favorability of their responses to LDL-C lowering with PCSK9 inhibitors? Video

    What did ODYSSEY Outcomes and FOURIER teach us about high-risk patients with diabetes and the relative favorability of their responses to LDL-C lowering with PCSK9 inhibitors?

    What LDL-C target goals should a consulting or treating medical cardiologist recommend for patients with Type 2 diabetes—with a known ACS event vs. diabetes alone as a risk factor? Video

    What LDL-C target goals should a consulting or treating medical cardiologist recommend for patients with Type 2 diabetes—with a known ACS event vs. diabetes alone as a risk factor?

    What have we learned from the ODYSSEY Outcomes pharmacoeconomic analysis that you and Professor Deepak Bhatt reported at the AHA 2018 Meeting? And what are the implications for the clinician-cardiologist who is making the case to payors? Video

    What have we learned from the ODYSSEY Outcomes pharmacoeconomic analysis that you and Professor Deepak Bhatt reported at the AHA 2018 Meeting? And what are the implications for the clinician-cardiologist who is making the case to payors?

    How exactly did you and your colleagues model the pharmacoeconomic effectiveness of alirocumab based on the actual results of the ODYSSEY Outcomes Trial? Video

    How exactly did you and your colleagues model the pharmacoeconomic effectiveness of alirocumab based on the actual results of the ODYSSEY Outcomes Trial?

    How do you approach the diabetic patient who also has a constellation of multiple high-risk features, above and beyond the underlay of diabetes? What is the relative and absolute benefit of employing PCSK9 inhibitors in this patient population? Video

    How do you approach the diabetic patient who also has a constellation of multiple high-risk features, above and beyond the underlay of diabetes? What is the relative and absolute benefit of employing PCSK9 inhibitors in this patient population?

    From a medical cardiologist and ACS expert perspective, can you identify which patients should undergo consideration for PCSK9-mediated LDL-C reduction and what risk factors should encourage CV specialists to pursue PCSK9-based therapies? Video

    From a medical cardiologist and ACS expert perspective, can you identify which patients should undergo consideration for PCSK9-mediated LDL-C reduction and what risk factors should encourage CV specialists to pursue PCSK9-based therapies?

    What should the approach be in patients who have had a coronary event with an LDL-C level of 70 mg/dL? Do the outcome studies with PCSK9 inhibitors provide an evidentiary roadmap for this common situation? Video

    What should the approach be in patients who have had a coronary event with an LDL-C level of 70 mg/dL? Do the outcome studies with PCSK9 inhibitors provide an evidentiary roadmap for this common situation?

    Disclaimer:
    Copyright © by CMEducation Resources, LLC All rights reserved. Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.
    Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.
    Content on this webcast is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This webcast is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This webcast is not intended for use by the layman.
    Opinions expressed herein are not necessarily those of CMEducation Resources, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.

    Clinical Webcasts®

    Powered by BroadcastMedBROADCASTMED